



## Stop the Drip: Tranexamic Acid Solution for Nosebleeds

### CLINICAL QUESTION

Can topical tranexamic acid treat epistaxis?

### BOTTOM LINE

**Tranexamic acid intravenous solution applied to a cotton pledget increases the proportion of patients who stop bleeding within 10 minutes from 55% (saline) to 82%. Based on 1 randomized controlled trial (RCT), tranexamic acid may be better than vasoconstrictors (ie. phenylephrine-lidocaine) with 90% stopping bleeding at 10 minutes versus 14% (vasoconstrictors). However, efficacy of combining agents is unclear.**

### EVIDENCE

- Results statistically significant unless indicated.
- Reporting RCTs due to different comparators. RCTs mostly used 500-1000mg of 100mg/ml tranexamic acid (TXA).
- TXA alone; 2 RCTs versus saline.
  - RCT, 152 participants, 500-1000mg tranexamic-acid:<sup>1</sup>
    - Proportion of patients who stopped bleeding within 10 minutes: 82% (1000mg) versus 72% (500mg) versus 55% (saline). Statistically significant for 1000mg versus saline only (PEER calculation), Number Needed to treat (NNT)=4.

- Proportion re-bleeding within 24 hours: 6% (1000mg) versus 10% (500mg) versus 29% (saline). (NNT)=5-6.
    - Other RCT, 90 participants: similar.<sup>2</sup>
- TXA versus vasoconstrictor; 1 RCT, 100 participants on ASA/clopidogrel.<sup>3</sup>
  - Mean bleeding time: 6.7 minutes versus 11.5 minutes (phenylephrine-lidocaine).
  - Stopped bleeding within 10 minutes: 90% versus 14% (phenylephrine-lidocaine), NNT=2.
  - Re-bleeding within 72 hours: 6% versus 20% (phenylephrine-lidocaine), NNT=8.
- TXA with phenylephrine-lidocaine versus phenylephrine-lidocaine; 1 RCT, 240 participants:<sup>4</sup>
  - Nasal packing: 50% versus 64% (phenylephrine-lidocaine alone), NNT=8.
  - Re-bleeding within 24 hours: 15% versus 30% (phenylephrine-lidocaine alone), NNT=7.
- TXA (200-400mg) after topical vasoconstrictor versus water; 1 RCT, 496 participants:<sup>5</sup>
  - Nasal packing (~42%), hospitalization (~45%): no difference
  - Limitations: Older patients (age~71) with co-morbidities, 65% on anti-coagulants, lower doses used.
- TXA versus nasal packing; RCTs showed equivalent<sup>2</sup> or superior to nasal packing.<sup>6-8</sup>
- Adverse events similar to placebo.<sup>5</sup>
- Limitations: No RCTs of TXA plus vasoconstrictor versus TXA alone, no RCTs in children.

## CONTEXT

- Epistaxis chief complaint in 1/313 emergency room visits. ~20% resolve with external pressure.<sup>9</sup>
- Role of tranexamic acid not clearly outlined in guidelines.<sup>10</sup>
- Evidence supporting the efficacy of topical vasoconstrictors in epistaxis is limited even though commonly used.
- Cost 10mL ~\$10,<sup>11</sup> IV solution applied cotton pledget prior to insertion into nostril.

## REFERENCES

1. Arikan C, Akyol PY. Sci Prog. 2024 Oct-Dec;107(4):368504241264993.
2. Akkan S, Çorbacioğlu ŞK, Aytar H, *et al.* Ann Emerg Med. 2019 Jul;74(1):72-78.
3. Amini K, Arabzadeh A, Jahed S, *et al.* Arch Acad Emerg Med. 2020 Nov 19;9(1):e6.
4. Hosseinalhashemi M, Jahangiri R, Faramarzi A, *et al.* Ann Emerg Med. 2022 Sep;80(3):182-188.
5. Reuben A, Appelboam A, Stevens KN, *et al.* Ann Emerg Med. 2021 Jun;77(6):631-640.
6. Chaitanya V, Manampuram MT, Sreelakshmi PS *et al.* Indian J Otolaryngol Head Neck Surg. 2024 Aug;76(4):3066-3070.

## AUTHORS

**Émélie Braschi**, MD PhD  
**Jennifer Young**, MD CCFP-EM

*Authors do not have any conflicts of interest to declare.*

7. Zahed R, Moharamzadeh P, AlizadehArasi S, *et al.* Am J Emerg Medicine. 2013 Sep;31(9):1389-1392.
8. Zahed R, Jazayeri MHM, Naderi A, *et al.* Acad Emerg Med. 2018 Mar;25(3):261-266.
9. Biadsee A, Gob A, Sowerby L. CMAJ. October 03, 2022 194 (38) E1322.
10. Tunkel DE, Anne S, Payne SC, *et al.* Otolaryngol Head Neck Surg. 2020 Jan;162(1\_suppl):S1-S38.
11. Tranexamic Acid Prices, Coupons, Copay Cards & Patient Assistance. <https://www.drugs.com/price-guide/tranexamic-acid>. Accessed on Nov 1<sup>st</sup> 2024.

---

**TOOLS FOR PRACTICE  
PROVIDED BY**



---

**IN PARTNERSHIP WITH**



**Tools for Practice** are peer reviewed and summarize practice-changing medical evidence for primary care. Coordinated by **Dr. Adrienne Lindblad**, the articles are developed by the Patients, Experience, Evidence, Research (PEER) team, and supported by the College of Family Physicians of Canada, and the Alberta, Ontario, and Saskatchewan Colleges of Family Physicians. Feedback is welcome and can be sent to [toolsforpractice@cfpc.ca](mailto:toolsforpractice@cfpc.ca). Archived articles can be found at [www.toolsforpractice.ca](http://www.toolsforpractice.ca)

*This communication reflects the opinion of the authors and does not necessarily mirror the perspective and policy of the College of Family Physicians of Canada.*